Williams Paul Anthony sold $25K of EBS

Williams Paul Anthony (SVP, Products Business) sold 3,000 shares of Emergent BioSolutions Inc. (EBS) at $8.40 on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Williams Paul Anthony
Published Jul 2, 2026, 4:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 5:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EBS
Neutral
high confidence
Mentioned
$EBS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EBSNeutralLow
01

Why it matters

This is a scheduled open-market sale by an SVP under a Rule 10b5-1 plan; it is more useful for monitoring insider activity than for forecasting near-term earnings or guidance.

02

Market read

Traders may note the insider sale for sentiment/positioning, but there is no new company-specific fundamental information.

03

What to watch

The disclosure does not indicate why shares were sold (taxes, diversification, scheduled plan), so any bearish interpretation is likely overstated without additional corroboration.

Relevance 2/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-02; sale executed 2026-07-01

Background

The article is an SEC Form 4 insider transaction disclosure for Emergent BioSolutions Inc. (EBS).

Company-level read

Ticker impact

$EBSNeutralHigh confidence
Context

SEC Form 4 shows Emergent BioSolutions SVP Paul Anthony Williams sold 3,000 shares at $8.40 on 2026-07-01 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this disclosure.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational or financial guidance changes.

Market effects

No clear read-across to biotech sector fundamentals from a single officer 10b5-1 sale.

None.

None.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may watch for follow-on sales or changes in selling patterns.

Key entities

  • Emergent BioSolutions Inc.

    Issuer of the Form 4 insider transaction; SVP Paul Anthony Williams sold shares under a 10b5-1 plan.

  • Paul Anthony Williams

    SVP, Products Business; reported open-market sale of 3,000 shares at $8.40 on 2026-07-01.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EBSMedAI 8/10

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

$EBSMedAI 8/10

Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary

Emergent BioSolutions reported Q3 2026 revenue of $110M, a 52.4% YoY decline, and a net loss of $32.7M, compared to a profit of $51.2M a year earlier. Nine-month revenue fell 16% to $500.4M, driven by lower NARCAN sales and declines in medical countermeasure products. The company reduced its workforce by 90 employees in August to cut costs.

$EBSMed

Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript

Emergent BioSolutions reported Q3 2026 revenue of $110M, within guidance, bringing YTD revenue to $500M. Adjusted EBITDA reached $128M (25% margin), with $122M in operating cash flow. The company highlighted progress in its transformation plan, including contract modifications and international sales. CFO Rich Lindahl announced his retirement, with Frank Vargo assuming the role in 2027. The company also discussed its role in biodefense and AI partnerships for clinical development.

$EBSMed

Emergent Biosolutions Q3 Earnings Call Highlights

Emergent Biosolutions reported Q3 cash of $176M, reduced gross debt by $179M YoY, and repurchased $75M in bonds. MCM revenue was $59M, with international sales contributing $72M. Naloxone market faced competition. 2026 revenue guidance updated to $600M-$645M. CFO to retire, interim replacement named. (EBS)